<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316912</url>
  </required_header>
  <id_info>
    <org_study_id>ATX2417/001/14</org_study_id>
    <nct_id>NCT02316912</nct_id>
  </id_info>
  <brief_title>First in Man Evaluation of Single and Multiple Doses of Oral ATX2417</brief_title>
  <official_title>Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atopix Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atopix Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in man evaluation of single and multiple doses of compound ATX2417 in healthy male
      volunteers. A double blind placebo controlled parallel group ascending dose design; up to
      five dose levels for the single dose and up to two dose levels for the multiple dose (8 days
      of dosing). Subjects will be screened to assure normal health prior to inclusion in the trial
      and will be monitored for safety (adverse events, vital signs, ECGs, safety labs) and
      pharmacokinetic profile. A fasted/fed comparison will also be included in the single
      ascending dose part of the trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts, A (single ascending dose including fasted/fed comparison)
      and B (multiple ascending dose). Part B will be conducted after a thorough review by the
      Sponsor and the Principal Investigator of the data arising from part A.

      Part A This will be a randomised, double blind, placebo controlled, parallel group titration
      of up to seven single dose levels of ATX2417. In each cohort, six subjects will receive
      active compound and two will receive placebo in a randomised fashion. At each dose level, 2
      subjects (1 subject will receive ATX2417 and 1 subject will receive placebo) will be dosed on
      Day 1 and the remaining 6 subjects will be dosed at least 24 hours later. Safety and
      pharmacokinetic observations will be made. There will be a minimum of two weeks between the
      first dosing day at each dose level. Safety and ATX2417 pharmacokinetic data will be reviewed
      prior to each dose escalation and, based on pharmacokinetic data, it is also possible to
      decrease the dose if the pharmacokinetic profile so indicates. This part will also include an
      assessment of the effect of a high fat breakfast on the absorption and pharmacokinetic
      profile of ATX 2417, performed at a dose predicted to be associated with therapeutic plasma
      concentrations.

      Part B Following completion of Part A, and selection of appropriate dose levels, Part B will
      be performed. This will be a randomised, double blind, placebo controlled, parallel group
      study of up to two dose levels of ATX2417 given once daily for eight days. In each cohort,
      six subjects will receive active compound and two will receive placebo in a randomised
      fashion. Safety and pharmacokinetic observations will be made.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>120 hours after dosing</time_frame>
    <description>Number of subjects with adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>120 hours after single dose</time_frame>
    <description>Area under concentration time curve at 120 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>120 hours after eighth dose</time_frame>
    <description>Area under concentration time curve at 120 hours</description>
  </secondary_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Single dose level 1 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 I mg tablet once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 2 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 2x1 mg tablet once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 3 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 5 mg tablet once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 4 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 4x5 mg tablets once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 5 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 to be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose level 1 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 dose to be determined once daily for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose level 2 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 dose to be determined once daily for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects one placebo tablet once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects one placebo tablet x2 once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects one placebo tablet once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 4 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects two placebo tablets once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 5 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects four placebo tablets once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose level 1 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects matching placebo(s) once daily for 8 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose level 2 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two subjects matching placebo(s) once daily for 8 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 6 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 to be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 7 active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six subjects ATX2417 to be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 6 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six subjects placeboto be determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose level 7 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Six subjects placebo to be determined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX2417</intervention_name>
    <description>Randomised double blind parallel group ascending dose assessment</description>
    <arm_group_label>Single dose level 1 active</arm_group_label>
    <arm_group_label>Single dose level 2 active</arm_group_label>
    <arm_group_label>Single dose level 3 active</arm_group_label>
    <arm_group_label>Single dose level 4 active</arm_group_label>
    <arm_group_label>Single dose level 5 active</arm_group_label>
    <arm_group_label>Multiple dose level 1 active</arm_group_label>
    <arm_group_label>Multiple dose level 2 active</arm_group_label>
    <arm_group_label>Single dose level 6 active</arm_group_label>
    <arm_group_label>Single dose level 7 active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomised double blind parallel group ascending dose assessment</description>
    <arm_group_label>Single dose level 1 placebo</arm_group_label>
    <arm_group_label>Single dose level 2 placebo</arm_group_label>
    <arm_group_label>Single dose level 3 placebo</arm_group_label>
    <arm_group_label>Single dose level 4 placebo</arm_group_label>
    <arm_group_label>Single dose level 5 placebo</arm_group_label>
    <arm_group_label>Multiple dose level 1 placebo</arm_group_label>
    <arm_group_label>Multiple dose level 2 placebo</arm_group_label>
    <arm_group_label>Single dose level 6 placebo</arm_group_label>
    <arm_group_label>Single dose level 7 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male subjects, any racial group

          2. Able to comply with the protocol

          3. Subjects with a Body Mass Index (BMI) of 21-28 (BMI = Body weight (kg) / (Height (m)2)

        Exclusion Criteria:

          1. A history of gastrointestinal disorder likely to influence drug absorption

          2. Receipt of any medication including over the counter preparations and vitamins within
             14 days of the first dose of study drug with the exception of paracetamol up to a
             maximum of 2 g daily

          3. Evidence of clinically significant renal, hepatic, cardiovascular or metabolic
             dysfunction

          4. A history of drug or alcohol abuse

          5. Inability to communicate well with the investigator (i.e., language problem, poor
             mental development or impaired cerebral function)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalid Abou Farha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Glamorgan</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

